38 results
8-K
EX-99.2
GKOS
Glaukos Corporation
1 May 24
Glaukos Announces First Quarter 2024 Financial Results
4:10pm
the company’s continued commitment and progress on its key corporate sustainability initiatives.
Over the course of 2023, Glaukos undertook several
8-K
EX-99.1
GKOS
Glaukos Corporation
28 Feb 24
Investor Presentation February 2024
7:00am
decades of investment and commitment
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity First-ever long
8-K
EX-99.2
GKOS
Glaukos Corporation
9 Jan 24
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
7:00am
decades of investment and commitment
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity First-ever
8-K
EX-99.2
hrk4l2uzp1
3 May 23
Glaukos Announces First Quarter 2023 Financial Results
4:10pm
8-K
EX-3.1
xbslu6znouz cfxlrznf
21 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-99.1
ewoomogj
2 Nov 22
Glaukos Corporation Announces Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.2
jci9m3dhvvi9w7kvhb71
3 Aug 22
Glaukos Corporation Announces Second Quarter 2022 Financial Results
4:17pm
8-K
EX-99.2
jo3yh74irk
4 May 22
Glaukos Corporation Announces First Quarter 2022 Financial Results
4:12pm
8-K
EX-99.1
tpa1 9c8wsp
20 Dec 21
Departure of Directors or Certain Officers
4:20pm
8-K
EX-99.1
peqnrimkdud cvrpe
4 Nov 21
Glaukos Corporation Announces Third Quarter 2021 Financial Results
4:18pm
8-K
EX-99.1
3e2i75a5xnsqva5mf6jv
5 May 21
Glaukos Corporation Announces First Quarter 2021 Financial Results
4:20pm
8-K
EX-99.1
76hp3858vycibu8hq7
25 Feb 21
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
4:16pm
8-K
EX-3.1
bpkpcv6 ec9659gfh
20 Nov 20
Amendments to Articles of Incorporation or Bylaws
4:47pm